
Sign up to save your podcasts
Or


In episode 37 of Derms and Conditions, our host James Q. Del Rosso, DO sits down with April W. Armstrong, MD, MPH and David E. Cohen, MD, MPH live at Fall Clinical 2022 in Las Vegas, NV to discuss highlights from the meeting.
This is a very unique episode of Derms and Conditions filled with clinical pearls for four conditions! Dr. Armstrong discusses two biologics that have great data for prurigo nodularis as well as a new topical JAK inhibitor for vitiligo. Dr. Cohen highlights some advances for atopic dermatitis while revealing the highly anticipated 2023 allergen of the year. Finally, the two share their thoughts on the landmark approval of deucravacitinib for psoriasis. Don’t miss hearing our KOLs discuss its novel mechanism, efficaciousness, and safety profile so that you can confidently answer your patients’ questions about this new therapy. Tune in today!
By Dermsquared4.9
5151 ratings
In episode 37 of Derms and Conditions, our host James Q. Del Rosso, DO sits down with April W. Armstrong, MD, MPH and David E. Cohen, MD, MPH live at Fall Clinical 2022 in Las Vegas, NV to discuss highlights from the meeting.
This is a very unique episode of Derms and Conditions filled with clinical pearls for four conditions! Dr. Armstrong discusses two biologics that have great data for prurigo nodularis as well as a new topical JAK inhibitor for vitiligo. Dr. Cohen highlights some advances for atopic dermatitis while revealing the highly anticipated 2023 allergen of the year. Finally, the two share their thoughts on the landmark approval of deucravacitinib for psoriasis. Don’t miss hearing our KOLs discuss its novel mechanism, efficaciousness, and safety profile so that you can confidently answer your patients’ questions about this new therapy. Tune in today!

67 Listeners

2,440 Listeners

1,135 Listeners

16 Listeners

14 Listeners

36 Listeners

382 Listeners

143 Listeners

6 Listeners

2 Listeners

9 Listeners

6 Listeners

6 Listeners

32 Listeners

0 Listeners